BrainsWay (NSDQ:BWAY) said today that a study shows that deep transcranial magnetic stimulation (dTMS) plus standard medication was significantly more effective at reducing depression levels among major depressive disorder (MDD) patients than standard medication alone. Researchers at the Psychiatric Hospital Sveti Ivan in Croatia conducted the 228-patient randomized controlled study independent of industry support. The […]
Brainsway prices downsized $28m IPO
Brainsway yesterday priced its initial public offering in the U.S. slightly below the terms it set earlier this month. The Jerusalem-based company, which is already publicly traded in Israel, said April 3 that it planned to float 2.5 million American Depository shares at roughly $11.94 apiece. Each ADS is would represent two ordinary shares, slated […]
Brainsway sets terms for $30m IPO
Brainsway this week set the terms on its forthcoming initial public offering in the U.S., saying it hopes to raise nearly $30 million. The Jerusalem-based company, which developed a transcranial magnetic stimulation device to treat psychological disorders, said it plans to float 2.5 million American Depository shares at roughly $11.94 apiece. Each ADS is slated […]
Brainsway registers for $30m IPO
Brainsway has registered for an upcoming initial public offering, looking to bring in $30 million to support its transcranial magnetic stimulation tech, according to a recently posed SEC filing. The Israel-based company said that it plans to list on the Nasdaq Global Market under the symbol “BWAY,” according to the filing. Brainsway develops and supports […]
FDA chooses 8 medtech companies for opioid crisis challenge
The FDA has selected eight medtech companies to develop devices to help reduce the country’s opioid abuse crisis. More than 250 companies submitted entries to the FDA Innovation Challenge: Devices to Prevent and Treat Opioid Use Disorder, announced in May. Those selected include Masimo Corp. and deep-brain-stimulation company Brainsway Ltd. The companies will be expected to […]
BrainsWay wins ‘historic milestone’ clearance to treat OCD
BrainsWay said it has won de novo clearance from the FDA for its deep transcranial magnetic stimulation (Deep TMS) system for treatment of obsessive-compulsive disorder (OCD) in adults. The clearance marks the second indication granted for BrainsWay Deep TMS, and the first noninvasive medical device clearance for the treatment of OCD. The FDA cleared the device […]
Brainsway wins FDA nod for OCD-treating TMS system
The FDA today said it granted de novo approval for Brainsway‘s deep transcranial magnetic stimulation system, now indicated for treating obsessive compulsive disorder. The TMS system uses magnetic fields to simulate nerves in the brain, and has been shown to reduce the severity of OCD in patients. A 100-patient randomized, multi-center study of the device […]
7 medtech stories we missed this week: May 11, 2018
From ReShape submitting an approval application to Health Canada to Conavi receiving FDA clearance, here are seven medtech stories we missed this week but thought were still worth mentioning. 1. ReShape submits for Health Canada approval of ReShape balloon ReShape announced in a May 10 press release that it has submitted an application to the Medical Devices Bureau […]
Transcranial magnetic stim dev Brainsway raises $9m
Transcranial magnetic stimulation device developer Brainsway has raised $8.5 million, according to a report from Globes Israel. The round was joined by The Phoenix Holdings and IBI Investment House, which has an existing 8% stake in the company. Israel-based Brainsway is developing magnetic stimulation helmets for treating neurological and psychiatric disorders, according to Globes Israel. […]
Medtech funding for the week of Mar. 10, 2014
Brainsway raises $11.8M for neurological stimulation
Israeli stimulation devices maker Brainsway (PINK:BRSYF) raised about $11.8 million (NIS 41 million) thanks to a private placement investment from Yelin Lapidot Investment House.
MassDevice Network
@MassDevice
LinkedIn
YouTube